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 Skeletal muscle atrophy is a result of an imbalance in protein synthesis and 
protein degradation. It is a part of the normal aging process, but also may occur in 
response to several stimuli including disease, injury, and disuse. Currently there is no 
truly effective pharmacological treatment for atrophy.  The best treatment is a healthy 
diet and exercise, however, sick and aging individuals are not always capable of 
participating in the appropriate activity. Therefore, exploration of the mechanisms 
contributing to atrophy is essential because this may lead to discovery of an effective 
therapeutic target. The ether-a-go-go related gene (Erg1a) K+ channel has been shown 
to contribute to atrophy by up-regulating ubiquitin proteasome proteolysis in mice.  
Recent studies have shown that it also increases the intracellular calcium concentration 
in skeletal muscle. The aim of this work is to investigate the modulation of the increased 
intracellular [Ca2+] and its potential downstream effects on calpain activity.  To do this, 
we overexpressed human ERG1A (HERG1A) in a mouse myoblast cell line (C2C12 
cells). Looking for the source of increased calcium levels we investigated the skeletal 
muscle specific, voltage gated calcium channel (CAV1.1). We were able to discover that 
ii 
 
there is a significant 2.3 fold increase in Cav1.1 gene expression. Conversely, upon 
immunoblotting the protein abundance of Cav1.1 had no detectable change. Calpains, 
which are calcium activated cysteine proteases take part in the degradation of 
myofilaments when they are activated via calcium. The activity of these calpains were 
shown to have a 25.7% higher level of activity in response to HERG expression. The 
change in calpain activity may be attributable to increased calpain transcription, 
translation or changes in their inhibitor, calpastatin. When gene expression was 
analyzed for calpains and calpastatin, no significant change was observed. However, 
after analysis of protein abundance a decrease was found in calpains 2 and 3, along 
with calpastatin, suggesting that HERG1A may indeed be effecting calpain abundance. 
With our data we were able to conclude that the increase in intracellular [Ca2+] due to 
the presence of HERG1A is not due to Cav1.1. We were able to report that an increase 
in calpain activity occurred in response to HERG1A within C2C12 cells, however this 
was not due to changes in gene expression, but their protein abundance appears to 
decrease in response to HERG1A.  
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CHAPTER 1 
INTRODUCTION 
Skeletal muscle comprises approximately 40% of the total human body weight 
and contains 50-75% of all bodily proteins. It has multiple functions within the human 
body. It converts chemical energy into mechanical energy that can then be used to 
support body posture and generate force and movement for everyday activities [1].  It 
contributes to basal energy metabolism and maintains the core body temperature while 
consuming the majority of oxygen and fuel used in the body.  It also functions to store 
substrates for both energy production and cell growth (e.g., carbohydrates and amino 
acids) [1] . Thus, an adequate amount of skeletal muscle tissue is necessary for good 
health and a reduction in skeletal muscle tissue will compromise health, potentially 
inhibiting the body’s ability to respond to illness and stress [1] .  Growth of skeletal 
muscle occurs by the process of myogenesis, in which myoblasts fuse together to form 
multinucleated myofibers. This growth process is maintained by a continuous, 
fluctuating balance between protein degradation and protein synthesis; however, when 
the rate of degradation increases or the rate of protein synthesis decreases muscle 
mass can be lost in a process known as atrophy. Skeletal muscle atrophy is defined as 
a decrease (equal to or greater than 5%) in muscle mass as a result of cellular 
shrinkage [2]. Indeed, certain external stimuli can interfere with the correct balance 
between protein synthesis and degradation and cause fully formed muscle cells to 
degrade at an accelerated rate. Muscle disuse, denervation, starvation, disease (e.g., 
diabetes and cancer), loss of neural input, along with the normal aging process are a 
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few of the events that can induce muscle atrophy [3]. Treatments  for skeletal muscle 
atrophy currently under study include administration of pharmaceuticals such as growth 
factors [4], beta-agonists [5], inhibitors of proteolysis [6, 7], stimulators of protein 
synthesis [8] and myostatin inhibitors [9-11]; however, these are not adequately 
effective.  Thus, further investigation into the mechanisms resulting in atrophy is needed 
to reveal new and improved targets for therapy.  
The contractile subunit of skeletal muscle is called the sarcomere (Figure 1).  
The sarcomere is primarily composed of myofilaments, namely actin and myosin (thin 
and thick filaments, respectively), which function to produce muscle contraction. Other 
proteins often referred to as “anchoring” proteins assist in stabilizing the sarcomere, 
these include titin, nebulin, α- actinin, and desmin [1]. Titin is an elastic protein that 
attaches to the Z disc and helps align and stabilize myosin. Nebulin is often referred to 
as actin’s “ruler” because it stabilizes actin, being approximately the same length as this 
filament. The α-actinin protein is found on the Z disc and serves as an anchoring point 
for actin to this structure. Lastly, desmin is a protein that lies along the Z disc and 
connects this structure with the sarcolemma and extracellular matrix (Figure 1) [1]. 
Contraction occurs when the myosin head “pulls” itself along the actin filament causing 
interdigitation of the actin and myosin filaments (Figure 1); proteins found along the 
actin filament known as troponin and tropomyosin produce this activity. Tropomyosin 
lies on the actin protein and blocks the binding sites on actin for the myosin heavy chain 
head.  Troponin lies on top of the tropomyosin. Once Ca2+ is released from the 
sarcoplasmic reticulum in response to an action potential, troponin binds calcium and 
this binding changes the conformation of tropomyosin to expose the myosin head 
3 
 
binding sites on the actin (Figure 2) [1]. Myosin may then bind actin repeatedly like a 
ratchet, causing the interdigitating of the filaments and thus contraction.  The 
degradation of these thin and thick contractile filaments is the primary cause of skeletal 
muscle atrophy; thus, reduction of actin and myosin proteins will lead to reduced muscle 
mass and strength.  
There are three primary proteolytic systems that can contribute to atrophy when 
active: the ubiquitin proteasome pathway (UPP), cathepsins, and calpains. The UPP 
has been reported to be the primary pathway that is responsible for the protein 
degradation that produces skeletal muscle atrophy. It consists of a series of enzymes 
which activate ubiquitin and attach it to target proteins, and a proteasome unit which 
degrades the ubiquitinated proteins [3]. Cathepsins, which are a type of cysteine 
protease, are secreted into the cytosol from the lysosome and initiate the lysosomal 
pathway to assist in the degradation of proteins [12]. Lastly, calpains, which are the 
focus of our study, are calcium activated cysteine proteases that are active during 
atrophic conditions. Specifically, we have focused on the conventional calpains, 1 and 
2, along with the skeletal muscle specific, calpain 3. Finally, we have also focused on 
calpastatin, which is a native protein inhibitor of the conventional calpains [13].  
Calpains are detected throughout the body and participate in various processes, 
including embryonic development and cell function, intracellular signaling, regulation of 
gene expression, modulation of the cell cycle, and even apoptosis [14]. Increases in 
calcium increase calpain activity.  In skeletal muscle, calpains have been shown to act 
upon anchoring proteins (e.g., titin, nebulin, and desmin), which attach the sarcomere’s 
myofilaments to the Z-disc [15]. The cleavage of these proteins subsequently releases 
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α-actinin and thus results in the release of the actin thin filament from the myofibril.  
Thus, the activation of calpains assists in the degradation of myofibers and the release 
of their constituent myofilaments (actin and myosin), allowing these proteins to be 
ubiquinated and consequently degraded by the proteasome [15, 16]. Calpains are 
additionally known to aid in modulation of signaling pathways. For example, the Akt 
pathway is known to modulate the balance of protein synthesis and degradation and 
studies have shown that increased calpain activity will decrease the activity of Akt. The 
decrease in Akt allows for a decrease in mTOR kinase activity, which contributes to up-
regulated protein synthesis. Decreased Akt activity also leads to an increase in the 
abundances of proteins FoxO1, 3 and GSK-3ß which, when present, lead to protein 
degradation. Thus, increased calpain activity results in a decrease in protein synthesis 
and an increase in protein degradation (Figure 3) [16]. The role of calpains does not end 
there. They have also been shown to degrade tropomyosin and troponin proteins, 
however, at a much slower rate than anchoring proteins [15]. Combined with the 
cleavage of titin, this degradation allows the removal of the thick filament from the 
myofibril. It is important to note that calpains do not cleave proteins into amino acids; 
rather they cleave specific proteins into large fragments [7]. Thus, calpain activity allows 
for the disassembly of the sarcomere, allowing actin and myosin to become accessible 
for ubiquitination and subsequent degradation by the proteasome [15-17]. 
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Figure 1. Organization of proteins within a sarcomere [18]. 
 
Figure 2. When bound with calcium troponin changes conformation and shifts the 
tropomyosin protein to expose myosin binding sites on actin, allowing the myosin head 
to pull itself along the actin filament [19]. 
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Figure 3.  Some consequences of calpain activation. 
The ERG1 voltage-gated potassium channel alpha subunit is a product of the 
ERG1 (ether-a-go-go related gene) gene, which is located on chromosome 7 in humans 
and spans approximately 33 kb. The gene encodes 15 exons and has three alternative 
transcription start sites along with two alternative termination sites, which allows for five 
unique transcripts (Figure 4) [20]. The ERG1a protein has six membrane-spanning 
domains, a conserved pore domain, and an N-terminus with numerous potential 
signaling domains such as a cyclic nucleotide-binding domain and a Per-Arnt-Sim 
(PAS) domain (Figure 5A) [20, 21].   The alternative splice variant ERG1b subunit is 
essentially identical to the 1a variant except that is has a truncated N-terminus.  The 1b 
is considered to be a cardiac specific isoform [20, 21], although there are reports of its 
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detection in brain and cancer cells [22, 23]. The main difference between the 1b variant 
and others is that the ERG1b lacks the first 373 amino acids found in 1a, and rather 
contains its own unique 36 amino acid sequence at the NH2 terminus [20, 21]. The 
ERG1 channel is a heteromultimer composed of four alpha subunits. Interestingly, it has 
been shown that the cardiac ERG1 channel is composed of two ERG1a proteins and 
two ERG1b proteins [21] while the skeletal muscle channel is solely composed of the 
ERG1a variant which will be the focus of this study [24]. 
 
Figure 4. Genomic structure of chromosome 7 including the location of the ERG 
gene (top, red line). The 5 transcript variants of ERG result from alternative transcription 
start and termination sites (bottom). Blue boxes indicate exon-coding regions, red areas 
signify 5’ and 3’ UTRs, and blue arrows represent introns [20]. 
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Figure 5. (A) Linear sequence of the HERG1A channel with domains color-coded. 
Dotted lines represent exon-exon junctions while arrows represent transcription start 
sites. (B) Extracellular view of the HERG1A channel (left) and intracellular view (right) 
color-coded to match the linear sequence in A. (C) Topology of two HERG1A subunits 
once again color-coded to match panels A and B [20]. 
ERG1 is well conserved across many mammalian tissues including brain and 
heart, but had not been reported in skeletal muscle until the report from the Pond and 
Hannon labs [24]. Within heart tissue the ERG1 potassium channel has been shown to 
conduct the IKr current and be partially responsible for the repolarization of the cardiac 
action potential [20, 21, 25]. Indeed, mutations found in human ERG1 (HERG1) can 
produce a form of long QT syndrome, (LQT2) an arrhythmia brought about by prolonged 
repolarization of the cardiac action potential that can lead to sudden cardiac death.  
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In 2006, the Pond and Hannon labs demonstrated that ERG1a expression and 
protein abundance increases in the skeletal muscle of mice in response to hind limb 
suspension and with tumor expression. Indeed, when ectopically expressed in the 
skeletal muscle of weight bearing mice, mouse ERG1a (MERG1A) was shown to induce 
atrophy. Further, when ERG1a was either pharmacologically or genetically blocked, the 
skeletal muscle atrophy normally caused by hind limb suspension was inhibited [24].  
Specifically, they reported that the MERG1A protein increased in Gastrocnemius 
muscles after 4 days of hind limb suspension (i.e., unweighting), prior to the onset of 
significant atrophy, and was still up-regulated after 7 days of hind limb suspension when 
significant atrophy was noted.  They also reported that the MERG1A channel was up-
regulated in the skeletal muscle of cachectic mice.  They further demonstrated that 
genetic and pharmacologic attenuation of MERG1A channel activity prevented atrophy 
in suspended mice and that expression of Merg1a was found to induce a decrease in 
cross sectional area of muscle fibers in weight bearing mice. Most importantly their 
findings concluded that the MERG1A channel participates in the initiation of atrophy by 
signaling for an increase in UPP activity [24]. 
More than half of the skeletal muscle wasting that occurs in response to 
immobilization has been shown to be caused by the UPP pathway (Figure 6). 
Specifically, this pathway is composed of three main enzymes (E1, E2, and E3) and a 
proteolytic unit called the proteasome.  E1 is an ubiquitin-activating enzyme which 
allows ubiquitin to be attached to ATP and then passed along to E2, which is known as 
the ubiquitin-conjugating enzyme. E3 ligases are the final enzymes and these transfer 
ubiquitin to the targeted protein substrate by ligation.  Polyubiquitination of a substrate 
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makes it a target for degradation by the proteasome [2, 15, 26]. MURF1 and 
Mafbx/ATROGIN1 are two muscle specific E3 ligases and are known to be up regulated 
in atrophic muscle [3]. ERG1a has since been shown to modulate the expression of the 
E3 ligase MURF1, however, it does not modulate expression of the E3 ligase 
Mafbx/ATROGIN1. This suggests that ERG1a participates in the process of skeletal 
muscle atrophy at least partially through modulation of the ubiquitin proteasome 
pathway [25].  
 
Figure 6. The ubiquitin proteasome pathway [2]. 
Calcium has multiple roles in skeletal muscle. One of the primary roles is 
initiation of excitation-contraction coupling (ECC) which requires M concentrations of 
calcium ions; however, at nM concentrations calcium also acts as a second messenger 
in cell signaling systems, modulating the expression of genes needed for growth and 
differentiation [27-30]. Two different types of calcium transients have been identified in 
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skeletal muscle, a fast and a slow component. The initial fast calcium release is linked 
to contraction while the second slow calcium release shows a response to 
depolarization that is unrelated to ECC. This slow release of calcium in response to 
depolarization results from an increase in inositol 1,4,5-triphosphate (IP3) [27]. IP3 binds 
to its receptor (IP3R) and leads to calcium release into the cytosol from the sarcoplasmic 
reticulum (SR). This calcium is then taken back into the SR via SERCA. The activation 
of the IP3R consequently leads to the slow calcium component [27, 31].  The slow 
calcium transient brought on by depolarization and the consequent increase in IP3 have 
been linked to activation of early genes in skeletal muscle, specifically c-fos, c-jun, egr-1 
along with P-ERK (MAPK/ERK pathway) and the cAMP response element-binding 
protein (P-CREB) [29].  
Human ERG1A (HERG1A) has been shown to increase the basal intracellular 
calcium concentration ([Ca2+]i) of SKBr3 breast cancer cells [32]. Indeed the Pond and 
Hockerman labs have also shown that HERG1A expression will increase the basal 
[Ca2+]i of C2C12 myotubes as well as produce a transient increase in the [Ca2+]i of 
myotubes in response to depolarization (Figure 7, unpublished data, Pratt, Hockerman, 
Pond).  However, the mechanism by which the HERG1A channel has this effect is not 
known.  Indeed, we hypothesized that HERG1A expression would increase calpain 
activity in C2C12 myotubes as a result of the increased calcium concentration.  Here, 
we perform studies designed to explore this hypothesis and the possible consequences 
of increased calcium activity in the C2C12 myotubes. 
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Figure 7. Fura2 dye experiments (340/380nm ratio) reveals a 34% increase in basal 
intracellular calcium levels ([Ca2+]i) in HERG1A transduced cells as opposed to GFP 
transduced control cells. (p<0.0001; n=90 control, n=87 HERG1A). Bars represent the 
mean while error bars represent the standard error from mean (mean ± SEM) 
(unpublished data, Pratt, Hockerman, and Pond). 
 The ultimate goal of the Pond lab is to explore the mechanism by which 
HERG1A affects skeletal muscle atrophy. Here, our focus will be on identifying the 
source of increased [Ca2+]i and its downstream effects on protein degradation, 
specifically calpain enzymes and the calpain inhibitor calpastatin (i.e., their activity, 
abundance, etc.).  We hypothesize that the increase in [Ca2+]i is not due to an increase 
in voltage gated calcium channels.  Further, we hypothesize that calpain activity will 
increase as a result of the increase in [Ca2+]i. Using an in vitro model, we have 
overexpressed HERG1A in C2C12 myotubes and produced a decrease in their area 
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thus simulating atrophy. We observed that in response to HERG1A overexpression, 
myotubes have an increase in voltage gated calcium channel 1.1 (Cav1.1) mRNA, 
however, at the protein level no difference was observed. This suggests that there is an 
increase in transcription but it is not being translated into a change in protein abundance 
– at least not a detectable change. Thus, it is not likely that the increase in calcium is a 
result of increased Cav1.1 channels.  We have also been able to show an increase in 
calpain activity in response to 48 hour HERG transduction. The detected increase in 
calpain activity was shown not to be a result of an increase in transcription of calpains 1, 
2, nor 3. Lastly, we investigated the amount of calpastatin present in response to 
HERG1A, results showed that calpastatin transcription is not affected by the presence 
of HERG1A. When immunoblots were performed no change in protein abundance was 
found in calpain 1. Interestingly, immunoblots for calpains 2 and 3 and calpastatin 
revealed that there was a statistically significant increase in their protein abundance 
(40.69%, 38.9%, and 37.7%, respectively). 
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CHAPTER 2 
METHODS AND MATERIALS 
Antibodies 
Anti-Cav1.1 (extracellular) (Alomone labs, Jerusalem, Israel, Cat #: ACC-314) 
Calpain-1 Polyclonal Antibody (BioVision, Milpitas, CA, Cat #: 3189-30T) 
Calpain-2 Polyclonal Antibody (BioVision, Milpitas, CA, Cat #: 3372-30T) 
Calpain-3 Polyclonal Antibody (ABclonal, Woburn, MA, Cat #: A11995) 
Calpastatin Polyclonal Antibody (ABclonal, Woburn, MA, Cat #: A7634) 
Cell Culture 
 C2C12 myoblasts were grown in Dulbecco’s Modification of Eagle’s Medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and maintained in a 
humidified incubator with 10% CO2 at 37⁰C. To differentiate myoblasts into myotubes, 
cells were grown in DMEM supplemented with 10% FBS to ~85% confluence. The FBS 
medium was then removed from the cells and replaced with DMEM medium 
supplemented with 2% heat inactivated horse serum to initiate differentiation. Cells were 
incubated for 4 days in order to terminally differentiate into myotubes.  
Collagen Coating of TC Plates 
 Due to an observed tendency for mature myotubes to release from the bottom of 
cell culture dishes, plates were treated with rat collagen prior to being seeded with cells. 
To coat the plates, 1mL of 1M acetic acid was added to 9mL of deionized water (or the 
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proportionate amount) and mixed to achieve a final concentration of 0.1M acetic acid. 
This solution was mixed with rat collagen to produce a final concentration of 1 mg/mL 
collagen. The plates were then coated with enough rat collagen solution to cover the 
bottom of the plate and these were then incubated for 1 hour at 37⁰C. After an hour, the 
liquid was removed and the plates were washed with PBS twice. Plates were left under 
UV light overnight and then covered with parafilm and stored in the refrigerator until 
needed. When the plates were required they were incubated at 37⁰C for 10 minutes 
before cells were plated. 
Viral Transduction of Cells 
At terminal differentiation (4 days post addition of horse serum medium), the 
myotubes were treated with 200 MOI virus (from a 2x1010pfu [plaque-forming units] 
stock suspension of viral particles) as was determined previously to produce HERG1A 
protein after 48 hours. The amount of virus needed was calculated by the equation:  
𝑋 ∙ 200 = 2 × 1010𝑝𝑓𝑢 ∙ 𝑌 
Where 𝑋 is the number of cells and 𝑌 is the amount of virus in milliliters which was then 
converted to microliters. One set of cells was treated with control GFP adeno-virus 
(VQAd EMPTY-eGFP; ViraQuest, New Liberty, IA) while the other received adeno-viral 
particles encoding the human ERG1A K+ channel (VQAd CMV Herg-GFP; ViraQuest, 
New Liberty, IA). The amount of virus was then carefully pipetted into the correct 
volume of DMEM supplemented with 2% horse serum needed for the amount of 
plates/wells and triturated slowly. The HS medium that was present on the plates was 
drawn off with a pipet and replaced with the 2% HS medium treated with virus. The cells 
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were then incubated for 48 hours and monitored via fluorescence to verify that the 
transduction was successful. 
RNA Isolation 
 For isolation of RNA cell cultures were rinsed with PBS followed by the 
addition of 0.5 mL cold Trizol reagent (Life Technologies; Carlsbad, CA) for one minute. 
Tissue culture plates (10 cm) with a confluent layer of C2C12 myotubes were then 
scraped with a clean lab spatula and this material was collected in a 1.5 mL Eppendorf 
tube. A 100 L aliquot (20% of original volume) of chloroform was then added to the 
Eppendorf tube and this was vortexed for 30 seconds. The Eppendorf tubes were then 
centrifuged for 15 minutes at 12,000 rpm at 4°C. Following centrifugation, the top 
aqueous layer in the Eppendorf tube (~250 L) was removed and placed into a clean 
1.5 mL Eppendorf tube. A 250 L aliquot of isopropanol was added to the aqueous 
solution, vortexed and incubated at room temperature for 10 minutes. The Eppendorf 
tubes were once again centrifuged for 10 minutes at 12,000 rpm at 4°C. The 
supernatant was decanted and 0.8 ml of 70% ethanol was pipetted onto the resultant 
pellet followed by centrifugation for 5 minutes at 12,000 rpm at 4°C.  The supernatant 
was again decanted and the excess ethanol was carefully suctioned off and the pellet 
was allowed to air dry for 10 minutes. The pellet was then dissolved in 15 L of DEPC 
treated water and incubated at 57°C for 10 minutes and finally vortexed briefly to 
precipitate all liquid. The RNA was then measured by UV spectrophotometry using a 
NanoDrop (NanoDrop ND-1000 spectrophotometer, Nanodrop Technologies, Thermo 
Fischer, Wilmington, DE).  
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DNase Digestion 
 The GOScript™ Reverse Transcription System Kit (Promega; Madison, 
WI) was used to degrade genomic DNA in the RNA samples using manufacturer’s 
instructions and reagents provided in the kit. Briefly, a volume containing 3.5 g of 
isolated RNA was brought to 8 L with DEPC treated water. A 1 L aliquot of 10X RQ1 
Reaction buffer and 1 L of RNase free DNase were added to the RNA and water. The 
reagents were then incubated in a thermocycler at 37°C for 30 minutes to degrade DNA 
and then the samples were incubated at 65°C for 10 minutes to denature the DNase 
enzyme. A 2 L aliquot of 50 μM oligo(dT) was added to each sample and incubated at 
70°C for 5 minutes, after which the samples were chilled on ice for 5 minutes. The 
sample tubes were then centrifuged lightly to collect the condensate.  
cDNA synthesis 
For the cDNA synthesis reaction, a reaction mixture was made with the following 
components per sample: 6 L 5X GoScript RT buffer; 3.6 L 25mM MgCl2; 3 L 0.1 M 
DTT;1 L 10 mM dNTPs; 2.9 L nuclease free water; and 1.5 L GoScript reverse 
transcriptase. An aliquot of this reaction mixture (18 L) was placed into an appropriate 
RNase- and DNase-free microtube along with 2 L of each sample. Samples were 
placed in a thermocycler to incubate at 25°C for 5 minutes, 42°C for 1 hour, and 70°C 
for 15 minutes.  Once synthesis was complete, the cDNA samples were stored at -20°C 
(final volume = 30 L). 
 
18 
 
Primer Design 
 Primers were designed using the NCBI Primer – BLAST program and DNA 
sequences downloaded from NCBI except where noted. The criteria used to design 
primers were as follows: amplicon length of 50 – 210 base pairs, primer length of 18 – 
23 nucleotides, a GC content of 35 – 65%, and a melting temperature between 57 – 
67C. The following sequences were used (Table 1). All primers were obtained from 
Integrated DNA Technologies (Coralville, IA). 
  
19 
 
Table 1. Sequences of RT-PCR primers.  
 
Primer Name (mouse) 
 
Primer Sequence 
5’ – 3’ 
 
Size 
(bp) 
 
Tm 
(°C) 
 
GC 
(%) 
 
Amplicon 
Size (bp) 
 
Merg1a Forward 
 
cctcgacaccatcatccgca 
 
20 
 
59.6 
 
55.0 
 
145 
 
Merg1a Reverse 
 
aggaaatcgcaggtgcaggg 
 
20 
 
60.3 
 
60.0 
 
 
18S Subunit Forward 
 
cgccgctagaggtgaaattct 
 
21 
 
57.2 
 
52.4 
 
101 
 
18S Subunit Reverse 
 
agaacgaaagtcggaggttc 
 
20 
 
57.0 
 
52.4 
 
 
Cav1.1 Forward 
 
gtcccaccaacaagatccgt 
 
20 
 
57.3 
 
55.0 
 
88 
 
Cav1.1 Reverse 
 
gctgagcaggatgaagagca 
 
20 
 
57.4 
 
55.0 
 
 
Cav1.1e Forward** 
 
ctaatcgtcatcggcagcat 
 
20 
 
55.1 
 
50.0 
 
59 
 
Cav1.1 embryo Reverse** 
 
tctcatctgggtcatcgatct 
 
21 
 
54.8 
 
47.6 
 
 
Cav1.2 Forward* 
 
atgcaagacgctatgggctat 
 
21 
 
56.5 
 
47.6 
 
201 
 
Cav1.2 Reverse* 
 
caggtagcctttgagatcttcttc 
 
24 
 
55.0 
 
45.8 
 
20 
 
 
Cav1.3 Forward 
 
gctggacatgctggttgttg 
 
24 
 
55.2 
 
41.7 
 
116 
 
Cav1.3 Reverse 
 
ttgattgctctgagaggccg 
 
22 
 
56.5 
 
50.0 
 
 
Calpain 1 Forward 
 
gctaccgtttgtctagcgtc 
 
20 
 
58.73 
 
55.0 
 
98 
 
Calpain 1 Reverse 
 
taactcctctgtcatcctctggt 
 
23 
 
59.99 
 
47.83 
 
 
Calpain 2 Forward 
 
ttttgtgcggtgtttggtcc 
 
20 
 
59.83 
 
50.0 
 
107 
 
Calpain 2 Reverse 
 
aactcagccacgaagcaagg 
 
20 
 
60.89 
 
55.0 
 
 
Calpain 3 Forward 
 
ttcacaggaggggtgacaga 
 
20 
 
60.11 
 
55.0 
 
122 
 
Calpain 3 Reverse 
 
ttcgtgccatcgtcaatggag 
 
21 
 
61.01 
 
52.38 
 
 
Calpastatin Forward 
 
gccttggatgacctgataga 
 
20 
 
53.8 
 
50.0 
 
115 
 
Calpastatin Reverse 
 
gtgcctcaaggtaggtagaa 
 
20 
 
53.7 
 
50.0 
 
*Primer sequence was obtained from B.Schlick et. al. [33].  
**Primer Sequence was obtained from Nasreen Sultana et. al. [34]. 
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Primer Efficiency Determination 
 To determine the efficiency of the primer sets, a standard curve was generated 
using dilutions (e.g., 1:2, 1:4, 1:8, 1:16, and 1:32) of an appropriate standard (known 
plasmid or cDNA from a known tissue sample, such as heart for Cav1.2 and adrenal 
glands for Cav1.3), which were assayed by real time PCR using a C1000 Thermocycler 
machine (BioRad; Hercules, CA).  Standards were assayed in triplicate and then 
standard Ct was plotted against the log of the standard concentration. Using Microsoft 
Excel (Excel 2013, Microsoft, Redmond, WA), the linearity was calculated using the R-
square method and the slope of the line was determined and used to calculate the 
efficiency of the primers:  10(-1/slope). Percentage determination was done by: 
efficiency
2
×
100. The primer efficiency was considered acceptable at 95 – 105% with R-square 
values of 0.985 or above for the standard curve. 
Quantitative Real Time PCR (qRT-PCR) 
 Primer stocks for quantitative real time PCR were diluted with nuclease free 
water so the final concentration of each primer was 100 M. Primers were then diluted 
1:5 to a final volume of 100 l (20 M), making a working solution. Master mixes were 
made so that 18 l of this mix would contain: 7 l of autoclaved water, 1 l of primer mix 
(forward and reverse primers diluted in autoclaved water) final concentration of 1 M, 
and 10 l of SYBR green. A master mix was made which contained primers for the gene 
of interest and a second master mix was made which contained primers for a “house-
keeping” gene for normalization.  An 18 l aliquot of the each master mix was loaded 
into wells of a 96 well plate (Thermo Scientific, Waltham, MA) in triplicate and a 2 l 
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aliquot of each cDNA sample was added to the triplicate wells, with the exception of a 
single triplicate set of wells which received a 2 L aliquot of non-template control (i.e., a 
sample which had undergone all steps of the process without any RNA) per master mix.  
An Applied Biosystems 7300 Real Time PCR machine was used for all qPCR work with 
HERG/Merg to determine Ct values (Applied Biosystems; Foster City, CA). For all other 
qPCR data a BioRad CFX96 Real Time System was used to determine Ct values 
(BioRad; Hercules, CA). To normalize the data, the average Ct values for the target 
gene were compared to that of the house-keeping18S rRNA (18S). The average Ct of 
each triplicate was taken for both the target gene and the reference 18S gene. The fold 
change was then determined via the 2−∆∆Ct (Livak) method (Bio Rad Laboratories, Real-
Time PCR Applications Guide, 2006) and an average Ct of each triplicate first taken 
(Ct).  
Ct(target) – Ct(ref) = ∆Ct, ∆Ct - ∆Ct(con, 0 hr) = ∆∆Ct,  2-∆∆Ct = normalized expression ratio. 
Protein Harvest 
 Medium was aspirated and the plates were then rinsed gently with 30-37⁰C PBS 
three times. A 0.3 ml aliquot of 10mM Tris 1mM EDTA (TE) containing 2% Triton X-100 
and protease inhibitors (listed below) were then rinsed over each plate surface with an 
Eppendorf tip or pipetteman while scraping the surface with the pipette tip. Plates were 
then scraped with rubber policeman or a Teflon stirrer. Cells and cell debris were 
aliquoted into an Eppendorf centrifuge tube and placed on ice. A 0.2 ml aliquot of TE 
buffer was added to the plate and scraped over the surface as before. The solid 
material was scraped into the liquid and pipetted into the Eppendorf tube and pooled 
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with the earlier aliquot. The sample was then triturated with a tuberculin syringe and 
23G1 needle until solid particles were broken up. The tubes were then left on ice and 
placed in the refrigerator for 30 minutes to solubilize. It was then triturated a second 
time with a syringe and needle for 1-2 minutes. Eppendorf tubes with material were then 
centrifuged in a tabletop centrifuge for 2 minutes at 15,000 rpm. If the supernatant 
appeared cloudy or large amounts of solid were present the supernatant was removed 
to a second Eppendorf tube and centrifuged a second time. The aliquot was then 
frozen, retaining a small amount (~20l) for protein microassay. 
Protease inhibitors per 100ml of TE buffer: 
500l of 100mM stock pefabloc or PMSF (in ethanol) (final = 0.5mM) 
100l of 1mM (0.7 mg/ml) stock pepstatin (final = 1mM) 
2.0ml of 50mM stock benzamidine (final = 1mM) 
200l of 2.0mg/ml stock aprotinin (final = 4μg/ml) 
1.0ml of 100mM stock Iodoacetamide (final = 1mM) 
1.0ml of 100mM stock 1,10-phenanthroline (final = 1mM) 
Protein Microassay 
 Protein assays were done using a DC Protein assay kit (BioRad, Hercules, CA) 
using the microplate assay protocol. Working reagent was made up using 20l of 
reagent S added to every ml of reagent A needed (A’). Protein standards were made 
using bovine albumin at concentrations of 0.25mg/ml to 2mg/ml in order to prepare a 
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standard curve. A 5l aliquot of both standards and samples were pipetted into the wells 
of a 96-well microtiter plate. Then 25l of reagent A’ was added to each well followed by 
200l of reagent B. The plate was gently mixed and allowed to sit at room temperature 
for 15 minutes. Absorbances were then read at 750nm using a Synergy H1 Hybrid 
Reader (BioTek Instruments, Winooski, VT). 
Western Blot 
 Polyacrylamide SDS gels (separating gel 7.5% and stacking gel 4% acrylamide) 
were poured. BioRad Kaleidoscope Precision Plus Protein Standards (BioRad, 
Hercules, CA; 12l) were used with each electrophoresis run. Sample protein (protein 
amounts as indicated in each figure, 20l) were combined with 5L of 5X sample 
diluting buffer (0.3M Tris, 50% glycerol, 5% SDS, 0.5M DTT, and 0.2% Bromophenol 
Blue) and boiled in water for five minutes. The gel was then loaded with standard and 
samples and electrophoresed at 200V until the dye front exited the gel. The proteins 
were then transferred to PVDF transfer membrane (BioRad, Hercules, CA 0.2μM pore 
size).  Specifically, the membrane was initially soaked in methanol, rinsed in deionized 
water, and then placed in transfer buffer (10% 10X electrode buffer, 20% methanol, and 
deionized water). Once electrophoresis was complete, the gel was removed and placed 
on the aforementioned membrane and filter papers and placed in a transfer apparatus 
(Trans-Blot® Cell; BioRad) filled with transfer buffer. A current was run through at 
400mAmps for an hour and a half. The gel was carefully removed and excess 
membrane was cut away and the lanes were cut out and separated according to the 
antibody into which each would be incubated. The membrane was rinsed in PBS 3 
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times for five minutes each rinse. The sample containing membrane was then incubated 
in a blocking buffer (0.2% I-Block (Applied Biosystems; Foster City, CA), 0.1% Tween-
20 in 1X PBS, pH 7.4) and placed on a rocker for one hour. The necessary primary 
antibody was diluted (per figure legends) in a second blocking buffer (5% NGS, 0.2% 
Triton X-100, 0.1% sodium azide in PBS) and the primary antibody was placed on top of 
the membrane and left in the refrigerator in a wet chamber overnight. The next day the 
membranes were removed from primary antibody and were rocked for 10 minutes each 
in two changes of I-block buffer (0.2% I-Block, 0.1% Tween-20, 1X PBS). It was then 
removed from the buffer and incubated in a goat anti-rabbit alkaline phosphatase (AP)-
conjugated secondary antibody (diluted 1:1000 in I-block buffer) for 1 hour. The 
secondary antibody was removed and the membranes were washed three times for 15 
minutes in I-block buffer. The membrane was then washed twice in assay buffer (0.1% 
Tween 20 in TBS). Membranes were then laid down on a plastic block and Immun-Star 
AP substrate (BioRad, Hercules, CA) at 37⁰C was applied to the membranes for five 
minutes. The substrate solution was then removed and the membranes were blotted 
with Kim Wipes before being wrapped in clear plastic wrap. These were taken to a dark 
room and developed using a SRX-101A film processor (Konica Minolta, Chiyoda, 
Tokyo, Japan). After films were developed, they were scanned into a computer and 
ImageJ was used to measure optical densities of each band.      
Calpain-Glo Assay 
 Myotubes were differentiated for four days in horse serum media in 24 well plates 
followed by transduction with 200MOI HERG1A or GFP virus (12 wells each). Wells 
were then washed with two changes of 37°C PBS. A Calpain-Glo™ Protease Assay kit 
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(Promega, Madison, WI) was used to assay calpain activity.  The kit included a Calpain-
Glo Buffer, Suc-LLVY-Glo Calpain Substrate, and Luciferin Detection Reagent which, 
when combined, is referred to as Calpain-Glo Reagent. A stock buffer solution of 0.2% 
Triton X-100 in PBS and 200nM epoxomicin (BostonBiochem, Cambridge, MA, Cat. #I-
110) was made in order to permeabilize the cells (Triton) and inhibit the proteasome 
(epoxomicin). To begin, 200μl of the 4 separate buffer solutions each containing either 
2.0mM EDTA, 2.0mM CaCl2, or buffer alone were added to 6 wells (3 Control, 3 HERG). 
These were allowed to sit at room temperature for 5 minutes to ensure the cells were 
permeabilized and the proteasome inhibited. After 5 minutes 200μl of the Calpain-Glo 
reagent was added to all wells and allowed to sit at room temperature for 15 minutes. A 
200μl aliquot of the liquid was removed to a white-walled 96 well plate and 
luminescence was read by a Synergy H1 Hybrid Reader (BioTek Instruments, Winooski, 
VT). The remaining well contents were scraped from the back of the plate, triturated 
using a syringe and 26 gauge needle and then centrifuged to remove solid material.  
The supernate was assayed for protein content using the BioRad DC kit (described 
above).  The protein data were used to normalize the calpain activity. 
Statistics 
In general, statistics were done using a simple student t-test and SAS (SAS Inc.; Carey, 
NC). Results were considered significant when p<0.05. 
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CHAPTER 3 
RESULTS 
Specific Aim I: An in vitro model of HERG1A Overexpression in C2C12 myotubes. 
ERG1 Protein Content in Myoblasts and Myotubes.  To study the effect of HERG1A 
expression on myotubes, we first had to develop an in vitro model overexpressing 
HERG1A. This first entailed determining the amount of native MERG1A protein 
detectable in both C2C12 myoblasts and 5 day differentiated myotubes. Western blot 
revealed a statistically significant 40.7% greater abundance of MERG1A protein in 
myotubes than in myoblasts (p<0.01; Figure 8). 
           
B. 
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Figure 8. Expression of MERG1A protein is 40.7% higher in myotubes than in 
myoblasts. (A) Western blot shows protein levels of MERG1A in undifferentiated 
myoblasts and myotubes (50g protein per lane). Protein extracted from mouse brain 
was used as a positive control. (B) To show that equal amounts of protein were loaded 
into each lane, the membrane was stained for protein with Coomassie blue (G-250; 
BioRad, Hercules, CA). (C) The mean optical densities from three samples are shown 
here with a bar graph.  The bars represent the mean of three samples while with the 
error bars revealing the standard error of the mean (mean ± SEM). 
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Overexpression of HERG1A in Myotubes.  We next wanted to determine to what 
extent the HERG1A protein would be overexpressed in response to the transduction of 
myotubes with HERG1A virus.  Thus, the HERG1A and control adenoviral particles, 
both encoding GFP, were transduced into myotubes. The HERG1A treated myotubes 
were found to have an increased amount of HERG1A protein while, as expected, the 
control myotubes showed no HERG1A protein present. Optical densities were 
determined, revealing that there was no difference in MERG1A protein levels between 
control and HERG1A-transfected cells (Figure 9).   
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Figure 9. HERG1A can be overexpressed in myotubes using viral particles.  (A) 
HERG1A and MERG1A protein (50g protein each lane) are detected in C2C12 
myotubes 48 hours after transduction with HERG1A virus whereas control cells solely 
express MERG1A. Protein extracted from mouse brain was used as a positive control 
and (B) the membrane was stained for protein using Coomassie blue stain to 
demonstrate that equal amounts of protein were loaded into each well. (C) The mean 
optical densities from three experiments were plotted as a bar graph. The bars 
represented the mean and error bars represented the standard error of the mean (mean 
± SEM). 
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Overexpression of HERG1A Induces Atrophy in Myotubes.  To explore further the 
effect of the HERG1A channel on muscle, we transduced myotubes with control and 
HERG1A-encoded virus and imaged the cells at 48 and 72 hours post-treatment (Figure 
10A). We measured the area of the myotubes and discovered that HERG1A treatment 
produced a significant 30.5% and 21.4% decrease in myotube area at 48 and 72 hours 
post transduction, respectively (p<0.01) (Figure 10B). At this point, we have ensured 
that our viral transduction is successful in penetrating the cell, translating the encoded 
protein, and decreasing the size of the cell, thus simulating atrophy in vitro. 
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Figure 10.  HERG1A expression in C2C12 myotubes induces a decrease in myotube 
area. (A) Images of control and HERG expressing myotubes at 48 hours post 
transduction.  Scale bar = 50 m.  (B) Myotube area was determined using ImageJ and 
revealed a significant 30.5% decrease in cell size when cells were treated with 
HERG1A. Bars representthe mean of three experiments with the standard error of the 
mean (mean ± SEM) represented by error bars (left to right n= 69, 63, 81, 78). 
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Our results have allowed us to demonstrate that we have a successful in vitro 
model of skeletal muscle atrophy resulting from over-expression of the voltage gated 
potassium channel HERG1A in C2C12 myotubes. Differentiated myotubes presented 
with a greater abundance of MERG1A protein than the undifferentiated myoblasts. 
Transduction with an adenovirus coding for HERG1A was shown to successfully 
synthesize the HERG1A protein within myotubes and cause a decrease in myotube 
area. This data combined allowed us to conclude that we have successfully simulated 
atrophy using a HERG1A encoded adenovirus in C2C12 myotubes. 
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Specific Aim 2: Investigation of the effect of HERG1A on voltage gated calcium 
channels. 
 Observation of the increase in intracellular calcium resulting from HERG1A 
overexpression (Figure 7) led us to question the source of this increased calcium.  We 
wanted to determine if the calcium was coming from the exterior through sarcolemmal 
L-type calcium channels or was it perhaps released from internal stores of calcium.  
Because the ERG1A channel is detected in the sarcolemmal membrane, where the 
Cav1.1 calcium channels are found in skeletal muscle, we turned our attention to the 
voltage gated calcium channel family (i.e., CAV, DHPR), specifically Cav1.1, 1.2, and 
1.3, and included the Cav1.1e splice variant found only in the embryonic stage.  
HERG1A Overexpression Does Not Affect Expression of Cav1.2 and 1.3. Cav1.1 
mRNA levels were not significantly different from controls at 48 hours after transduction 
(Figure 11A) which is when we detected an increase in intracellular calcium 
concentration (Figure 7). The embryonic splice variant, Cav1.1e, was also examined, 
however, no difference in that mRNA level in response to HERG1A was detected 
(Figure 11B). Interestingly, we did detect a significant 2.26 fold increase in Cav1.1 
mRNA at 72 hours after transduction with the HERG1A virus (Figure 11A); however, the 
increase in intracellular calcium concentration was detected prior to this time point. As 
expected Cav1.2 and 1.3 were not expressed in the skeletal muscle of mice nor in the 
C2C12 cells even after treatment with HERG1A (data not shown).  
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Figure 11. Cav1.1 channel mRNA increases in HERG1A treated myotubes at 72 hours 
after transduction.  (A) Expression of HERG1A in C2C12 myotubes shows a significant 
2.3 fold increase in voltage gated calcium channel 1.1 (Cav1.1) gene expression 72 
hours post transduction, although there is no significant increase at 48 hours post 
transduction when the increase in intracellular calcium concentration is noted. (B) There 
was no significant difference in the amount of gene expression of the embryonic voltage 
gated calcium channel (Cav1.1e). Gene expression was compared to that of an 18S 
positive control. Bars represent means while error bars represent the standard error of 
the mean (mean ± SEM; n=3). 
In order to support the real time PCR data, an immunoblot was performed on 
C2C12 myotubes that were treated with either control or HERG1A virus (Figure 12). 
The cells were transduced for 96 hours. Note: This time point is 24 hours past the time 
point at which we saw the increase in mRNA which would allow enough time for 
transcription and translation of the voltage gated calcium channel to take place. Our 
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results show that there was no change in the abundance of protein in the myotubes at 
this time, although we saw an increase of mRNA expression through qPCR. We 
suspect that the small increase in Cav1.1 transcription detected by qPCR is either not 
physiologically significant enough to produce an increase in translation and thus protein 
abundance or the difference in protein abundance is not detectable. 
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Figure 12. Cav1.1 protein abundance did not change in response to HERG1A 
expression in C2C12 myotubes.  (A) Immunoblot for the L-type voltage gated calcium 
channel Cav1.1 (65g protein per lane). (B) Coomassie blue stain of the PVDF 
membrane for protein shows that equal amounts of protein were added to each lane. 
(C) No significant difference in the amount of protein was detected in HERG1A treated 
cells compared to those of the control cells at 96 hours after transduction with the 
HERG1A virus.  Bars represent means while error bars represent the standard error of 
the mean. 
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Specific Aim 3: Investigation of the effects of HERG1A-modulations of calpain activity. 
 Because HERG1A transduction results in increased intracellular calcium 
concentrations (Figure 7; [32]), we next wanted to investigate the downstream effects of 
this increase. Specifically, we began by monitoring activity of the calcium-activated 
calpain enzymes.  Cells were treated with 1mM final concentration of calcium to ensure 
that calpain activity could be measured and 1mM EDTA, a calcium chelating agent, was 
used to remove calcium from the system to yield a baseline level of non-calcium 
activated proteolytic activity. We used a Calpain-Glo assay kit (ProMega; Madison, WI) 
to monitor the combined activities of both calpain 1 and 2 and observed a 25.7% 
increase in basal calpain activity at 48 hours after transduction with HERG1A encoded 
viral particles (Figure 13). 
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Figure 13. Calpain activity was increased by a significant 25.7% in HERG1A 
treated C2C12 myotubes.  The calpain activity in the calcium treated control cells was 
19.2% greater than that in the EDTA treated control cells, but the difference was not 
statistically significant. Bars represent means and error bars represent standard error 
from the mean (mean ± SEM; n=3). 
Calpain enzymes are calcium activated and thus the activity will increase with 
increased intracellular calcium.  However, we cannot assume that the increased calcium 
is the only explanation for the increased calpain activity.  Other possible causes include: 
increases in calpain transcription and/or calpain protein levels or a decrease in 
calpastatin (a conventional native calpain inhibitor) transcription and/or its protein levels. 
Thus, we asked if calpain and calpastatin transcription levels (i.e., amount of mRNA 
produced) changed in response to HERG1A treatment. We used quantitative real time 
PCR and revealed that, although HERG1A treatment may produce a potential small 
trend of calpain 2 increase over time for 72 hours post viral transduction, it does not 
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produce a statistically significant change in calpain 2 gene expression for 84 hours after 
viral treatment (Figure 14). Further, no change in gene expression was detected for 
calpains 1 or 3 (data not shown). 
 
Figure 14. Expression of HERG1A in C2C12 myotubes did not produce a significant 
difference in calpain 2 gene expression. Bars represent means and error bars represent 
standard error from mean (mean ± SEM; n=3). 
 Immunoblots were performed to determine if there was any change in the 
amount of calpastatin or specific calpain protein in response to HERG1A treatment. For 
calpain 1, the optical densities of both bands in the doublet were measured and the 
statistics performed show that there is no difference in calpain 1 protein abundance 
(Figure 15). 
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Figure 15. Calpain 1 protein abundance was not affected by HERG1A treatment.  (A) 
Immunoblot of myotube lysates for calpain 1 (60g) reveals that there is no significant 
difference in the amount of calpain 1 protein in HERG1A treated myotubes compared to 
those of the control at 48 hours after transduction.  (B) Coomassie blue stain of PVDF 
membrane proteins shows that equal amounts of protein were loaded into each lane. 
(C) HERG1A treatment of myotubes did not affect significantly affect calpain 1 protein 
abundance.  The bars represent the means while error bars representing the standard 
error of the mean (mean ± SEM; n=3). 
 Calpain 2, when autolyzed and hence activated, has been seen to appear as two 
separate bands as stated previously. Figure 16 demonstrates this doublet found at 
~75Kd. Our results show that there is in fact a 40.69% decrease in calpain 2 (i.e., m-
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calpain) in response to HERG1A treatment. 
 
Figure 16. There is a 40.69% decrease in calpain 2 protein abundance in HERG1A 
transduced myotubes.  (A) Immunoblot for calpain 2 protein (60g per lane).  (B) To 
show that equal amounts of protein were loaded into each lane, the membrane was 
stained for protein with Coomassie blue. (C) HERG treatment resulted in decreased 
calpain 2 protein abundance.  Bars represent the mean of three samples while error 
bars represent the standard error from the mean (mean ± SEM; n=3). 
Calpain 3 is a skeletal muscle specific calpain that is not calcium dependent and, 
like other calpains, is believed to take part in the degradation of anchoring proteins. 
However, it is also suggested that calpain 3 takes part in the remodeling of the 
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sarcomere in times of cellular stress. We immunoblotted for calpain 3 protein and 
discovered that there is indeed a significant 38.9% decrease in calpain 3 protein 
abundance in response to HERG1A treatment (Figure 17). 
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Figure 17. There is a significant 38.9% reduction of calpain 3 protein in C2C12 
myotubes in response to HERG1A expression. A. Immunoblot of calpain 3 (60g protein 
per lane). B. Coomassie blue protein stain of transferred PVDF membrane 
demonstrates that equal amounts of protein were added to each well. C. A significant 
23.48% reduction of calpain 3 protein was observed. Bars represent the mean of three 
samples with error bars representing the standard error from the mean (mean ± SEM; 
n=3). 
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Calpastatin, as previously, stated is a native inhibitor of conventional calpains. 
Therefore, we were interested in investigating the effect of HERG1A treatment on 
calpastatin transcription and protein levels. Again using C2C12 myotubes and 
quantitative real time PCR, we measured the amount of calpastatin mRNA present in 
response to HERG1A treatment. Our findings revealed that there was no significant 
change in calpastatin mRNA in response to HERG1A treatment over 84 hours. (Figure 
18).   
 
Figure 18. Quantitative PCR shows that there was no significant change in calpastatin 
gene expression in response to HERG1A expression.  The fold change in calpastatin 
mRNA showed no significant difference when compared to the 18S reference gene. 
Bars represent the mean and error bars represent the standard error of the mean (mean 
± SEM; n=3). 
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 Immunoblots were done to observe the amount of calpastatin protein. The results 
show that there is a significant 37.7% decrease in calpastatin abundance found in the 
HERG1A transduced cells as opposed to control cells (Figure 19).  
 
Figure 19. Calpastatin protein abundance was decreased by a significant 37.72% in 
myotubes treated with HERG1A.  A. Immunoblot of control and HERG1A treated 
myotubes (60g protein per lane).  B. Coomassie blue protein stain of transferred PVDF 
membrane demonstrates that equal amounts of protein were added to each well.  C. 
Calpastatin protein abundance decreases in response to HERG1A.  Bars represent the 
mean of three samples while error bars represent the standard error from the mean 
(mean ± SEM; n=3). 
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CHAPTER 4 
DISCUSSION 
The ERG1a voltage-gated K+ channel is responsible for late repolarization of the 
cardiac action potential and was thought to be absent from skeletal muscle [23, 35], 
however, the Pond and Hannon labs demonstrated that this protein is detectable in 
atrophying skeletal muscle [24]. Consequent studies have shown that ERG1a 
expression leads to an increase in the E3 ubiquitin ligase MURF1 and contributes to 
activation of the ubiquitin proteasome proteolysis known to contribute to skeletal muscle 
atrophy [24, 25]. A new study has now shown that ERG1a expression also increases 
the amount of [Ca2+]i in C2C12 myotubes (unpublished data, Pratt, Hockerman, Pond 
2018) (Figure 6). However, the source and downstream effects of the calcium increase 
have yet to be investigated.  Here we have initiated these studies. 
We have shown that HERG1A increases intracellular calcium in C2C12 
myotubes.  There are numerous mechanisms by which this could occur.  For example 
the IP3 pathway, in which a G coupled receptor (GPCR) activates phospholipase C 
(PLC), which in turn cleaves phosphatidylinositol 4, 5 bisphosphate (PIP2) into IP3 and 
diacylglycerol (DAG). The IP3 binds to its receptor, IP3R, yielding a release of calcium 
from its internal SR stores into the cytoplasm. Therefore, any changes in IP3 levels can 
change the amount of intracellular calcium, because of release from the SR [36]. 
Another protein known as smooth endoplasmic reticular calcium ATPase (SERCA) is 
found within the SR membrane and is responsible for transporting calcium back into the 
SR. Decreases in SERCA activity could reduce the return of calcium to internal stores, 
48 
 
thus allowing a buildup of [Ca2+]i in the cytoplasm and a reduction in Ca2+ concentration 
within the SR [36]. Lastly, the focus of this study are the Cav1.1 channels which are 
found along the sarcolemmal membrane and also in t-tubules. Changes in voltage along 
the t-tubules allows for a conformational change that affects ryanodine receptors within 
the SR allowing for calcium release, this in turn leads to excitation contraction coupling 
(ECC). Any changes in the Cav1.1 channel abundance or activity may lead to changes 
in the release of calcium from the SR [36]. Because ERG1a is a membrane bound 
protein detected on cardiac t-tubules [21, 37] and in the I-band of skeletal muscle where 
t-tubules are located (unpublished data, Zampieri and Pond), we thought it would be 
possible for ERG1a to have an effect on the L-type voltage-gated calcium channel 
Cav1.1. Cav1.1 is specific to the skeletal muscle membrane and is accepted to be the 
voltage sensor for excitation contraction coupling (ECC) in this tissue. Cav1.2 and 1.3 
have not been reported in skeletal muscle, but are detected in cardiac muscle and 
adrenal glands, respectively. Cav1.1 works by sensing an action potential that moves 
down the t-tubules. Once this action potential is recognized, the Cav1.1 channel 
undergoes a conformational change which allows it to interact physically with the 
ryanodine receptors to release calcium from stores in the sarcoplasmic reticulum [28, 
30, 38, 39]. This calcium release initiates ECC. Once ECC has occurred, reuptake of 
calcium into the SR occurs SERCA [38]. In a 2016 study by Sultana and colleagues 
reported that during maturation an embryological Cav1.1 splice variant, that excludes 
exon 29 of Cav1.1 (Cav1.1e), was found. After maturation this splice variant is replaced 
by an adult splice variant that includes exon 29 [28, 40]. It is suggested that the 
embryological splice variant differs from the adult in that it is much more sensitive to 
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voltage changes and spends an increased amount of time in the “open” state.  Because 
it remains in the open state longer, Cav1.1e conducts much larger calcium currents as 
opposed to its adult counterpart. This small change in the channel’s structure allows 
calcium to be better regulated in adult muscle as opposed to developing muscle [40]. 
However, skeletal muscle is always adapting to demand and the Sultana study noted 
that knockout of Cav1.1e appeared to have effects on skeletal muscle similar to that of 
endurance training. Further investigation revealed Cav1.1e affected muscle fiber type 
composition in mice, causing an increase in slow type muscle fibers. Consequences of 
this change include: reduced tetanic, maximal twitch and grip force. Additionally, 
Cav1.1e and its increase in calcium flux appears to cause mitochondrial damage [34]. 
For this reason it is reasonable for us to hypothesize that Cav1.1 or its variant may 
produce an increase of calcium from internal stores. However, our investigation 
revealed that neither the Cav1.1 nor the Cav1.1e channel is affected by the presence of 
ERG1a. However, it is still possible that ERG1a affects Cav1.1 channel kinetics.  This 
study is beyond the scope of this project and will be conducted in collaboration with a 
lab that focuses on electrophysiology. 
Another possibility is that ERG1a affects calcium levels by modulation of IP3. A 
previous study done by Perez-Neut [32] used a HERG activator (NS1643) on SkBr3 
breast cancer cells and found that indeed HERG activation leads to an increase in 
[Ca2+]i which promotes UPP activation and degradation of the cell cycle regulator 
protein, cyclin E2. Furthermore, activation of HERG via NS1643 hyperpolarized the 
membrane potential of the SkBr3 cells which are otherwise non-excitable. Their report 
suggested that hyperpolarization may perhaps increase intracellular negative charge 
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leading to the entry of positively charged calcium into the cells. By blocking voltage 
gated calcium channels using CoCl2 and activating HERG, a large increase in [Ca2+]i 
was discovered, these results suggested to them that the calcium entry was not a result 
of voltage gated calcium channel activity. Instead, they hypothesized that the inositol 
signaling pathway (IP3) may have some effect on calcium entry. This data along with 
our own suggest that the Cav1.1 channel is not involved with this increase in [Ca2+]i.  
Indeed, our lab now has preliminary data which suggests that intracellular calcium 
stores are involved in the increased [Ca2+]i (unpublished data, Pratt, Hockerman and 
Pond).  
We were also able to demonstrate that in the presence of HERG1A, myotubes 
had an increased amount of calpain activity. At this time it is not possible to discern if 
calpains 1 and 2 are modulated differently and, if so, how.  That is, is one of these 
isoforms transcribed or translated more than the other? Or is one activated more so 
than the other as a result of different effects on localized calcium concentration? The 
calpain system is complicated, and the activation of calpains is disputed. One thing that 
is agreed upon is that calpains must be autocatalyzed in order to be activated, 
specifically, on the N terminus [13, 16, 41, 42]. Indeed, the autolysis can be noted in our 
immunoblots (Figure 13-15) where multiple bands are seen [43]. The largest amount of 
controversy however concerns how calpains are activated. Calpain 1 has been shown 
to be at half maximal activity at low Ca2+ concentration (3-50 µM) while Calpain 2 
reaches half maximal activity at higher concentrations (400-800 µM). Taken together, 
our lab’s unpublished data showing that HERG1A expression in C2C12 myotubes yields 
an increase in [Ca2+]i combined with the results reported here which show that HERG1A 
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expression produces increased calpain activity, suggest that HERG1A is increasing 
calpain activity by increasing intracellular calcium concentration.  However, it is possible 
that there is an increased abundance of calpain 1 and/or calpain 2 protein(s) or that 
there is a decrease in the abundance of the native calpain inhibitor calpastatin. 
Calpains 1 and 2 are known as “conventional” calpains and are found throughout 
the body. Here we report a decrease in calpain 2 protein abundance in C2C12 
myotubes in response to HERG1A expression while calpain 1 shows no detectable 
change in protein abundance. These data are aligned with the quantitative PCR data 
which demonstrate that there is no change in transcription of calpain 1 or 2 genes.  
Indeed, one would expect there to be no increase in calpain proteins without an 
increase in gene expression, although there could still be an increase in the protein as a 
result of decreased proteolysis.  Because we see a decrease in calpain 2 without a 
change in transcription of that gene, we can speculate that the calpain 2 protein may be 
undergoing an increased level of degradation.  Is it possible that the HERG1A protein is 
increasing ubiquitin proteasome proteolysis of calpain 2?  
Calpains 1 and 2 are known to be upregulated during skeletal muscle atrophy 
caused by hind limb suspension, in a 2015 article by Shenkman and colleagues they 
inhibited calpain activity using the calpain inhibitor PD150606 [44]. Their results 
demonstrated that blocking calpain activity reduced the activation of calpain 1 gene 
expression and attenuated skeletal muscle atrophy. Mafbx/ATROGIN expression was 
also decreased in their experiments, however, there was no change in MURF1 
expression, suggesting that although calpains affect Mafbx gene expression they have 
no effect on Murf1. In 2006, Fareed and colleagues [7] reported that calpain inhibition 
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also deterred muscle proteolysis induced by sepsis, however, they reported that this 
was independent of Mafbx and Murf1/ATROGIN gene expression. Interestingly, the 
Pond and Hannon labs showed that Merg1a expression in mouse skeletal muscle 
increased Murf1 transcription and translation, but not that of Mafbx/ATROGIN [25].  The 
data suggest that ERG1A indeed has an effect on expression of UPP components, but 
does not suggest any connection with calcium up-regulation or increased calpain 
activity. Indeed, we find no report describing any calcium dependence by the UPP.  
Indeed, calpains are known to degrade skeletal muscle anchor proteins (e.g., titin, -
actinin, etc.) and, thereby release contractile proteins (i.e., actin and myosin) which are 
then degraded by the UPP [15, 45, 46].  We suggest that ERG1a may participate in the 
coordination of this effort by affecting both UPP and calpain activities. 
Our results have shown that not only does calpain 2 protein abundance 
decrease, but calpain 3 protein abundance decreases as well. Calpain 3 is skeletal 
muscle specific and the absence or reduction of this protein leads to limb-girdle 
muscular dystrophy type 2A (LGMD2A) in humans [13, 41, 42, 47-50]. It is also 
interesting in that its regulation is not controlled solely by calcium but also by sodium 
concentrations; however, the physiological relevance of this discovery is debated [42, 
51]. In vitro it has been shown that the Ca2+ concentration needed for calpain 3 to 
become completely active (in the absence of sodium) is 0.1mM. Whereas in the 
absence of calcium the Na+ concentration needed is much larger for activation, being 
100mM. However, when both ions are present they act together and decrease the 
concentration needed for either ion for calpain activation [37]. In vivo experiments have 
been done to observe the Ca2+ concentration that is necessary to cause autolysis 
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(activation) in skeletal muscle tissue. The findings concluded that increased levels of 
calcium (200nM) were sufficient to autolyze ~20% of endogenous calpain 3 in a resting 
muscle fiber. The calpain activity, however, was dependent on the exposure duration 
and the presence of ATP. If the Ca2+ concentration became high enough, then ATP was 
not needed.  It appears that the ATP increased the calpain 3 sensitivity to Ca2+ [49, 50]. 
It has been suggested, using calpain 3 knock out mice, that calpain 3 acts upstream of 
the UPP, although it is uncertain if calpain 3 directly cleaves proteins to make them 
accessible for ubiquitination [47]. What makes calpain 3 interesting is that it is not only 
known to break down proteins, but also takes part in remodeling of the sarcomere in 
response to cellular damage such as atrophy [42, 47]. It is proposed that calpain 3 is 
actually localized to the myofibrillar structure. In vitro it has been reported that calpain 3 
targets include Z-disk proteins such as titin, filamin C, talin, and myosin light chain 1. 
This is supportive of a role for calpains in sarcomeric remodeling in response to cellular 
damage. In a report by Murphy and colleagues [41] they found that in response to 
eccentric exercise calpain 3 is autolyzed (activated). This would mean that calpain 3 is 
responding to the accumulation of minor damage to the sarcomere resulting from 
exercise by remodeling/repairing the structure; this occurrence is absent from those with 
LGMD2A. In a second report in 2010 Murphy [46] mentions that calpain 3 is not 
detected until later in development, following myoblast proliferation and fusion, this 
could explain why LGMD2A is a late onset disease (20-40 years of age), accumulated 
damage is not repaired due to the absence of calpain 3, leading to muscle wasting. 
Evidence has shown that the absence of calpain 3 may lead to a reduction in protein 
turnover and cause the accumulation of proteins that are damaged or misfolded. An 
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increase in misfolded and damaged proteins can lead to cellular stress. Indeed, studies 
have revealed an increase in heat shock proteins in response to the absence of calpain 
3. This in turn may lead to cellular stress and toxicity, thus leading to muscle pathology 
(i.e., atrophy, dystrophy) [47, 52].  
Calpastatin is a native calpain inhibitor which assists in maintaining calpain 
activity by inhibiting conventional calpains 1 and 2, but not calpain 3.  A decrease in 
calpastatin protein decreases the ability of calpains to be regulated by inhibition. 
Calpastatin requires calcium in order to bind to calpains, but the concentration that is 
required is dependent on the calpain type [15]. When calcium concentrations rise, 
calpain activity is increased, thus calpastatin is needed to regulate their activity [13]. In 
our investigation of calpastatin the decrease in its protein abundance correlates with our 
calpain activity results. That is, in the absence of calpastatin, it would be expected to 
see an increase in calpain activity because it is no longer being inhibited by calpastatin. 
In summary, our results suggest that voltage gated calcium channels are in fact 
not the cause of HERG1A-modulated increases in [Ca2+]i.  It is possible, therefore, that 
[Ca2+]i is affected by a different mechanism such as a change in IP3 abundance or the 
ability of SERCA to reuptake calcium into the SR. We also provide evidence that 
ERG1a increases calpain activity in myotubes, likely resulting from the increase in 
[Ca2+]i. Our observations of decreased calpain 2 and 3 abundance could be a result of 
their degradation, perhaps resulting from a feedback loop to decrease proteolysis 
despite or because of the increased calcium concentration. The decrease in calpain 3 
may also be related to a decreased ability to remodel the sarcomere after atrophy, 
however, this possibility would require much additional investigation. Furthermore, the 
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decrease in calpastatin protein abundance may contribute to the increase in calpain 
activity that may also result from increased calcium concentration. Overall, our results 
suggest that HERG1A modulates intracellular calcium and calpain activity.  Indeed, its 
interaction with calcium and calpains may work upstream of the UPP, and indeed 
modulate the UPP, having a multi-faceted modulatory effect on skeletal muscle atrophy. 
Indeed, ERG1a will likely never be a target for pharmacological treatments of atrophy, 
however, continuing study of this protein may reveal other possible targets to combat 
atrophy.  
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